Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

CTSO has been the subject of a number of other reports. HC Wainwright reiterated a neutral rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Tuesday, May 7th. B. Riley reiterated a buy rating and set a $3.00 price objective on shares of Cytosorbents in a research note on Wednesday, May 15th.

Cytosorbents Trading Down 3.6 %

Shares of NASDAQ:CTSO opened at $0.90 on Friday. The stock has a 50 day moving average of $0.89 and a 200 day moving average of $1.06. The company has a market cap of $48.88 million, a PE ratio of -1.53 and a beta of 0.62. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.10. Cytosorbents has a 12-month low of $0.78 and a 12-month high of $4.29.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). The company had revenue of $9.79 million during the quarter, compared to the consensus estimate of $9.78 million. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. During the same period in the previous year, the company posted ($0.17) EPS. As a group, equities research analysts expect that Cytosorbents will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avenir Corp boosted its stake in Cytosorbents by 4.0% in the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after purchasing an additional 121,294 shares during the period. CM Management LLC raised its holdings in shares of Cytosorbents by 98.8% during the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after acquiring an additional 410,000 shares in the last quarter. Key Client Fiduciary Advisors LLC raised its holdings in shares of Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after acquiring an additional 22,557 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares in the last quarter. Finally, Skylands Capital LLC raised its holdings in shares of Cytosorbents by 10.5% during the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after acquiring an additional 309,543 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.